English, Article edition: Economic Implications of the Use of Basiliximab in Addition to Triple Immunosuppressive Therapy in Renal Allograft Recipients: A UK Perspective Stephen J. Walters; Malcolm Whitfield; Ronald L. Akehurst; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/119753
Physical Description
  • article
Language
  • English

Edition details

Title
  • Economic Implications of the Use of Basiliximab in Addition to Triple Immunosuppressive Therapy in Renal Allograft Recipients: A UK Perspective
Author
  • Stephen J. Walters
  • Malcolm Whitfield
  • Ronald L. Akehurst
  • James B. Chilcott
Physical Description
  • article
Notes
  • Objective: To compare resource use and costs in renal transplant recipients treated with basiliximab or placebo plus triple immunosuppressive therapy. Design: International randomised, double-blind, placebo-controlled trial; economic evaluation undertaken alongside the efficacy trial. The economic evaluation was performed from a UK National Health Service hospital perspective. Setting: 31 centres in 12 countries. Participants: 345 renal transplant recipients were enrolled; 340 were randomised (basiliximab 168; placebo 172) and included in the intention-to-treat analysis. Intervention: Treatment with placebo or basiliximab (20mg intravenous bolus) on day 0 and day 4 after transplantation. Main outcome measures: Resource utilisation in multiple categories and treatment costs for basiliximab and placebo-treated patients during the 6-month post-transplantation period. Results: No statistically significant differences were found in any of the economically important categories of resource use or in the mean cost of treatment per person across the whole trial. The mean cost of treatment, including the cost of basiliximab, was Lstg 16 095 for basiliximab recipients and Lstg 15 864 (1997/​1998 costs) for placebo recipients, a mean difference of Lstg 231 (95% CI: -Lstg 1983 to Lstg 2446), which was not significant. Basiliximab treatment led to a significant reduction in acute rejection episodes (basiliximab 20.8%; placebo 34.9%; p =​ 0.005). Conclusions: Basiliximab therapy confers a significant clinical benefit to renal transplant recipients without increasing overall treatment costs.
  • Basiliximab, Cost analysis, Immunosuppressants, Pharmacoeconomics, Renal transplant rejection, Resource use
  • RePEc:wkh:phecon:v:21:y:2003:i:2:p:129-138
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment